Oramed Pharmaceuticals Inc.
http://www.oramed.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oramed Pharmaceuticals Inc.
Oramed Failure Highlights Insurmountable Challenge Of Oral Insulin Delivery
Oramed's attempts to advance an oral formulation of insulin for type 2 diabetes patients have been scuppered with a Phase III fail that has sunk the stock.
Akero’s Phase II Success Could Augur Brighter Days For NASH R&D
With Akero’s FGF21 analog showing ability to reduce fibrosis and resolve non-alcoholic steatohepatitis, some analysts think classmate BIO89-100 could yield a better overall profile. NASH data are starting to pour in.
Finance Watch: Coronavirus-Related Stock Market Meltdown Didn’t Stop Passage Bio IPO
Public Company Edition: The gene therapy firm’s IPO priced at $18 and ended its first day up 23.3% at $22.20 but fell to $21.50 when stocks recovered on 2 March. Also, RedHill raised $115m for product launches and Movantik purchase, and Avadel raised $65m to compete with Jazz.
Pipeline Watch: Phase III Starts With VX-445, Reproxalap And AVXS-101
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice